# Nuclide record cu-64-sar-bispsma (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/cu-64-sar-bispsma/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "cu-64-sar-bispsma" ;
  schema:name "Copper-64 SAR-bisPSMA"@en ;
  schema:alternateName "64Cu-SAR-bisPSMA"@en, "64Cu-bisPSMA"@en ;
  schema:description "An experimental PET tracer for prostate cancer that binds the same target as approved PSMA scans (PSMA) but, because its radioactive tag lasts longer, can be re-imaged a day later to catch small deposits the first picture missed. It is not yet approved for sale."@en ;
  schema:url <https://nuclide.cc/drugs/cu-64-sar-bispsma/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5039>, <https://pubmed.ncbi.nlm.nih.gov/41904043/>, <https://clinicaltrials.gov/study/NCT04868604> ;
  nuclide:status "phase-3" ;
  nuclide:tag "PSMA", "copper-64", "theranostic pair", "investigational" ;
  nuclide:modality "PET tracer" ;
  nuclide:related <https://nuclide.cc/drugs/tc-99m-psma-imaging/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/cu-64/>, <https://nuclide.cc/isotopes/cu-67/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate-high-risk/>, <https://nuclide.cc/indications/prostate-bcr/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/pet-ct/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/clarity-pharmaceuticals/> ;
  nuclide:trials <https://nuclide.cc/trials/nct04868604/> .